^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GEN-009

i
Other names: GEN-009, cancer vaccine program, GEN 009
Associations
Company:
Genocea
Drug class:
Immunostimulant
Related drugs:
Associations
over2years
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (clinicaltrials.gov)
P1/2, N=24, Completed, Genocea Biosciences, Inc. | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009
over3years
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (clinicaltrials.gov)
P1/2, N=24, Active, not recruiting, Genocea Biosciences, Inc. | N=99 --> 24 | Trial completion date: Dec 2022 --> Mar 2022 | Trial primary completion date: Dec 2022 --> Mar 2022
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009
over3years
[VIRTUAL] InhibigensTM subvert otherwise-efficacious cancer vaccines and immunotherapies in conjunction with alterations in the tumor microenvironment (AACR 2021)
Genocea’s GEN-009 and GEN-011 phase 1/2 clinical trials utilize ATLAS to identify optimal neoantigens and omit Inhibigens from cancer vaccines and T cell therapies. Ongoing exploration of Inhibigen phenotypes and mechanisms will illuminate new paradigms of cancer immunology and potentially pave the way for novel cancer immunotherapies.
IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
GEN-009 • GEN-011
over4years
[VIRTUAL] Inclusion of inhibitory neoantigens can abolish efficacy of otherwise protective therapeutic anti-tumor vaccines (AACR-II 2020)
These data promote rational methods for neoantigen identification and highlight the potential advantages of excluding deleterious inhibigens from cancer vaccines and immunotherapies. GEN-009, a personalized cancer vaccine filtered for inclusion of only ATLAS-identified neoantigens (excluding inhibigens) is currently being evaluated in a Phase 1/2a clinical trial (NCT03633110).
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3)
|
LAG3 expression
|
GEN-009